Vipin Suri, Catamaran Bio CSO

Cata­ma­ran Bio sails in­to the CAR-NK wa­ters with a $42M launch round

Cata­ma­ran Bio’s found­ing mem­bers de­cid­ed to jump in­to the CAR-NK game last De­cem­ber over drinks at a trendy bar in Boston.

They were sit­ting around a ta­ble, dis­cussing an MD An­der­son study which pro­vid­ed some of the first clin­i­cal proof that nat­ur­al killer (NK) cells can be reengi­neered to at­tack tu­mors, much like CAR-T ther­a­pies. It was a “long and live­ly” dis­cus­sion, COO Mark Boshar re­calls. And by the time it was over, they had a start­ing point to launch a com­pa­ny.

“The ‘ide­al’ cell ther­a­py ap­proach would come from a holis­tic ap­proach — not a sin­gle linch­pin tech­nol­o­gy — in or­der to make progress be­yond the lim­i­ta­tions of ear­ly gen­er­a­tion prod­ucts,” Boshar wrote in a state­ment.

On Mon­day, Cata­ma­ran Bio emerged from stealth with $42 mil­lion in Se­ries A and seed fund­ing to de­vel­op what Boshar called the “holy grail” of cell ther­a­pies: off-the-shelf CAR-NK drugs made with donor cells to treat sol­id tu­mors.

Cata­ma­ran’s ther­a­pies will do two key things: at­tack sol­id tu­mor cells and the tu­mor mi­croen­vi­ron­ment, which sur­rounds the cells like a force field, CSO Vipin Suri told End­points News. In the hopes of get­ting around the cell ther­a­py man­u­fac­tur­ing bot­tle­neck, the biotech is us­ing a non-vi­ral trans­po­son sys­tem to de­liv­er the ge­net­ic pay­loads, rather than vi­ral vec­tors.

Un­like CAR-T treat­ments — which re­quire the long and cost­ly process of draw­ing a pa­tient’s own cells, treat­ing them and rein­ject­ing them — CAR-NK ther­a­pies can be made with donor cells. That’s be­cause donor T cells would like­ly trig­ger graft-ver­sus-host dis­ease, while for­eign NK cells don’t. The end goal is a cell ther­a­py that doesn’t look like a trip to the hos­pi­tal, Suri said.

“The idea is very much to have an off-the-shelf ther­a­py such that … when a physi­cian de­ter­mines that a pa­tient can ben­e­fit from cell ther­a­py, it is avail­able to be ad­min­is­tered as a ther­a­py right then, or short­ly there­after,” he told End­points News. 

Cata­ma­ran cur­rent­ly has two pro­grams, dubbed the TAIL­WIND Plat­form, which Suri ex­pects to en­ter the clin­ic in the next few years. De­vel­op­ment will be fund­ed by the Se­ries A, which was led by Sofinno­va Part­ners and Light­stone Ven­tures, with help from found­ing in­vestor SV Health In­vestors, as well as Take­da Ven­tures and Astel­las Ven­ture Man­age­ment.

The CAR-NK field is abound with new play­ers, led by MD An­der­son and Take­da, who said they’re look­ing to ini­ti­ate a piv­otal tri­al next year. Then there’s J&J-backed Fate Ther­a­peu­tics, which was cleared for its first CAR-NK clin­i­cal tri­al in Sep­tem­ber; Nkar­ta re­cent­ly dosed the first par­tic­i­pant in a clin­i­cal tri­al, and says a sec­ond IND is com­ing in Q1 of 2021; and ONK Ther­a­peu­tics, which said in Oc­to­ber that it’s about two years out from an IND.

“All these com­pa­nies have great teams, but we re­al­ly be­lieve that the team that Kevin (Po­jasek), Mark and Vipin put to­geth­er is a tru­ly dif­fer­en­ti­at­ed com­pa­ny,” SV Health man­ag­ing part­ner Houman Ashrafi­an told End­points

Houman Ashrafi­an

The team of sci­en­tif­ic founders in­cludes George Wash­ing­ton Uni­ver­si­ty pro­fes­sor Cather­ine Bol­lard, who’s di­rec­tor of the Cen­ter for Can­cer Im­munol­o­gy Re­search at the Chil­dren’s Na­tion­al Re­search In­sti­tute, and Uni­ver­si­ty of Min­neso­ta as­sis­tant pro­fes­sor Bran­den Mo­ri­ar­i­ty, who holds patents in key ar­eas, in­clud­ing for tech­nolo­gies us­ing DNA trans­po­son sys­tems. There’s al­so CMO Chris Car­pen­ter, who pre­vi­ous­ly served as CMO of Ru­bius Ther­a­peu­tics af­ter spend­ing time at GSK and Mer­ck, and se­nior VP of re­search Ce­leste Richard­son, who hails from Ob­sid­i­an Ther­a­peu­tics and No­var­tis.

“Cata­ma­ran to us sym­bol­izes the jour­ney. Our jour­ney is to broad­en the reach of cell ther­a­py for pa­tients in more in­di­ca­tions,” Suri said.

This sto­ry has been up­dat­ed to clar­i­fy that Nkar­ta has re­cent­ly dosed the first pa­tient in its clin­i­cal tri­al.

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Ivan Cheung, Eisai US chairman and CEO

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

In the first look at Phase III data for lecanemab, Eisai and Biogen’s follow-up Alzheimer’s drug to the embattled Aduhelm launch, results show the drug passed with flying colors on a test looking at memory, problem solving and other dementia metrics.

One of the most-watched Alzheimer’s therapies in the clinic, lecanemab met the study’s primary goal on the CDR-SB — Clinical Dementia Rating-Sum of Boxes — giving the biotech the confidence to ask for full approval in the US, EU and Japan by next March 31. The experimental drug reduced clinical decline on the scale by 27% compared to placebo at 18 months, the companies said Tuesday night Eastern time and Wednesday morning in Japan.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Gilead names 'k­ing­pin­s' in coun­ter­feit HIV med law­suit

Gilead is mounting its counterfeit drug lawsuit, naming two “kingpins” and a complex network of conspirators who allegedly sold imitation bottles of its HIV meds, some of which ended up in US pharmacies.

The pharma giant on Wednesday provided an update on what it called a “large-scale, sophisticated counterfeiting conspiracy,” accusing two new defendants of “leading and orchestrating” a scheme to sell hundreds of millions of dollars in illegitimate drugs posing as meds such as Biktarvy and Descovy.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

Vlad Coric, Biohaven CEO (Photo Credit: Andrew Venditti)

As Amy­lyx de­ci­sion waits in the wings, Bio­haven’s ALS drug sinks (again) in plat­form tri­al

The FDA’s decision on Amylyx’s ALS drug is set to come out sometime Thursday. In a space with few drugs, any approval would be a major landmark.

But elsewhere in the ALS field, things are a bit more tepid.

Thursday morning, Biohaven announced that its drug verdiperstat failed its arm of an ALS platform trial led by Massachusetts General Hospital. According to a press release, the drug did not meet its primary endpoint — improvement on an ALS functional status test — or any key secondary endpoints at 24 weeks. The trial had enrolled 167 patients, giving them either verdiperstat or placebo twice a day.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Work taking place in the clean rooms at Vor (Credit: Vor)

Vor Bio opts to keep man­u­fac­tur­ing op­er­a­tions in-house for de­vel­op­ing stem cell, CAR-T ther­a­pies

While it is not uncommon for a biotech to go down the route of having the product manufactured by a contract organization, one small biotech is looking to keep its card close to its chest.

Vor Biopharma has started manufacturing operations at an in-house facility at its HQ in Cambridge, MA after beginning construction last summer.

According to the biotech, the facility aims to develop Vor’s hematopoietic stem cells (eHSCs) and CAR-T therapies for patients with blood cancers. The site will initially manufacture a clinical supply of its candidate VCAR33allo to support its IND, which is slated to be submitted in the first half of next year. It also plans to transfer the production of VOR33 to the facility. Vor is getting to work quickly as engineering runs for VCAR33allo has started this week.

Aim­ing for fourth nod, Sarep­ta files an­oth­er DMD gene ther­a­py to FDA; Ax­some head­ed to­ward mi­graine re­sub­mis­sion

Sarepta Therapeutics has filed the data needed for an FDA accelerated approval, which would be the biotech’s fourth if granted by the agency.

The biotech has yet to complete confirmatory trials for those first three conditional nods. The filing for its fourth Duchenne muscular dystrophy treatment, disclosed Thursday, is not a surprise. Sarepta said in late-July it would do so after releasing positive results for the Roche-partnered gene therapy.

Tar­sus looks to raise aware­ness of eye­lid mite dis­ease in cam­paign aimed at eye­care spe­cial­ists

Eyelid mite disease may be “gross” but it’s also fairly common, affecting about 25 million people in the US.

Called demodex blepharitis, it’s a well-known condition among eyecare professionals, but they often don’t always realize how common it is. Tarsus Pharmaceuticals wants to change that with a new awareness campaign called “Look at the Lids.”

The campaign and website debut Thursday — just three weeks after Tarsus filed for FDA approval for a drug that treats the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Marcelo Bigal, Ventus Therapeutics CEO

No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

As a drug target, the NLRP3 inflammasome has drawn serious interest from Big Pharma, inspiring a series of M&A deals from Novartis and Roche on top of venture investments by others. Now Novo Nordisk is jumping on the bandwagon — and the Danish pharma giant is taking the target where it knows best.

Novo Nordisk is getting its NLRP3 inhibitors from Ventus Therapeutics, a Versant-backed startup that set out to make some of the best NLRP3 drugs out there by incorporating new insights into the structure of the target complex.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.